Nektar Therapeutics Schedule 13G passive stakes

Investment firm Two Seas Capital LP, along with its GP and CIO Sina Toussi, has disclosed beneficial ownership of 3,092,234 shares, representing 9.1% of Nektar Therapeutics' common stock as of June 30, 2026.

Several Biotechnology Value Funds have updated their beneficial ownership filings for Nektar Therapeutics, reporting a combined stake of 7.1% as of June 30, 2026.

Vanguard Capital Management has reported a beneficial ownership stake of 5.17% in Nektar Therapeutics, holding over 1.7 million shares.

Biotechnology Value Fund and associated entities have reported a 9.8% beneficial ownership stake in Nektar Therapeutics.

FMR LLC, through its subsidiaries, has reported beneficial ownership of 15.0% of Nektar Therapeutics' common stock as of March 31, 2026.

Two Seas Capital LP has filed a Schedule 13G reporting a 6.8% beneficial ownership stake in Nektar Therapeutics.

The Vanguard Group has reported a 0% beneficial ownership in Nektar Therapeutics following an internal realignment, disaggregating its reporting.

FMR LLC and Abigail P. Johnson have reported an 11.1% beneficial ownership stake in Nektar Therapeutics common stock.

A group of affiliated entities, including G1 Execution Services, LLC and Susquehanna, disclosed a 4.0% passive beneficial ownership stake in Nektar Therapeutics.

The Vanguard Group has reported a 5.04% beneficial ownership stake in Nektar Therapeutics, holding over 1 million shares.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, reported a 2.20% beneficial ownership stake in Nektar Therapeutics as of September 30, 2025.

TCG Crossover entities and Chen Yu report 0% beneficial ownership of Nektar Therapeutics, indicating a full divestment of their previously held stake.

Susquehanna Portfolio Strategies, LLC and Susquehanna Securities, LLC have jointly reported a 6.3% passive beneficial ownership in Nektar Therapeutics common stock.

The Vanguard Group has filed an amended Schedule 13G, reporting a 4.98% beneficial ownership stake in Nektar Therapeutics common stock.

Millennium Management LLC and affiliated entities have disclosed a 3.0% passive beneficial ownership stake in Nektar Therapeutics common stock as of September 30, 2025.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, has disclosed a passive 5.72% beneficial ownership stake in Nektar Therapeutics.

TCG Crossover Fund II, L.P. and affiliates report a 9.3% beneficial ownership stake in Nektar Therapeutics, including common stock and pre-funded warrants.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a passive beneficial ownership of 1.6% of Nektar Therapeutics' common stock as of June 30, 2025.

A group of investment entities led by Biotechnology Value Fund, L.P. and Mark N. Lampert has disclosed a collective beneficial ownership of 7.4% of Nektar Therapeutics' common stock.

Millennium Management LLC, along with its affiliates Integrated Core Strategies (US) LLC, Millennium Group Management LLC, and Israel A. Englander, have disclosed beneficial ownership of over 5% of Nektar Therapeutics' common stock.

Samlyn Capital, LLC, along with Samlyn, LP and Robert Pohly, has filed an amended Schedule 13G indicating a complete divestment of their beneficial ownership in Nektar Therapeutics, now holding 0% of the common stock.

BlackRock, Inc. has filed an amended Schedule 13G, revealing a 6.7% beneficial ownership stake in Nektar Therapeutics as of March 31, 2025.

Samlyn Capital, LLC, along with Samlyn, LP and Robert Pohly, has disclosed a passive beneficial ownership of 5.2% of Nektar Therapeutics' common stock as of December 31, 2024.

Eventide Asset Management, along with Finny Kuruvilla and Robin C. John, has disclosed a beneficial ownership of 3.61% of Nektar Therapeutics' common stock as of December 31, 2024.

Deep Track Capital and its affiliates have filed an amended Schedule 13G, disclosing a 1.07% beneficial ownership stake in Nektar Therapeutics as of December 31, 2024.